Clinical Trials
12 trialsNCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT03027245 2022-07-13
IRENE
Eisai Inc.
Completed
NCT02921828 2022-07-05
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene
Completed
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02922543 2022-06-14
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
Completed
NCT01775254 2018-12-06
The Inland Northwest Colon Cancer Survivor's Study
Washington State University
Completed
NCT03065478 2018-09-06
STEFANO
Swiss Medical Food AG
Completed
NCT01689610 2018-06-20
NABUCCO
iOMEDICO AG
Completed
NCT01697839 2018-03-05
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
Oncotherapeutics
Completed
NCT02549534 2017-10-27
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Indiana University
Completed
NCT01982591 2017-06-15
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Fox Chase Cancer Center
Completed
NCT00956033 2014-12-24
Skin Biopsies in Chemotherapy-Induced Neuropathy
Erasmus Medical Center
Completed